Not Yet Recruiting
Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma
NCT06903273
- Conditions
- Adenocarcinoma, Biliary Tract Cancer (BTC), Biliary Tract Diseases, +9 more
- Locations
-
- National Cheng Kung University Hospital Tainan, Taiwan